U.S. Markets closed

The Female Health Company (FHCO)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.070.00 (0.00%)
At close: 3:58PM EDT
People also watch
GLDDFCBCFLLFISIFCSC

The Female Health Company

4400 Biscayne Boulevard
Suite 888
Miami, FL 33137
United States
312-595-9123
http://www.veruhealthcare.com

SectorConsumer Goods
IndustryPersonal Products
Full Time Employees155

Key Executives

NameTitlePayExercisedAge
Mr. O. B. ParrishCo-Founder and Vice Chairman175.16kN/A84
Dr. Mitchell S. Steiner M.D., F.A.C.SChief Exec. Officer, Pres and DirectorN/AN/A56
Mr. Daniel HainesChief Financial Officer and Chief Operating OfficerN/AN/A35
Dr. Harry Fisch M.D., F.A.C.S.Chief Corp. Officer and DirectorN/AN/A58
Mr. Brian James GrochChief Commercial OfficerN/AN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

The Female Health Company, a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus. The company primarily serves global agencies, non-government organizations, ministries of health, and other governmental agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It has operations in the United States, Brazil, Zimbabwe, South Africa, Angola, the Democratic Republic of the Congo, Tanzania, Malaysia, Spain, France, the United Kingdom, and internationally. The company was founded in 1896 and is headquartered in Miami, Florida.

Corporate Governance

The Female Health Company’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.